SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001213900-23-028115
Filing Date
2023-04-07
Accepted
2023-04-06 21:07:44
Documents
1
Group Members
FORESITE CAPITAL FUND V, L.P.FORESITE CAPITAL MANAGEMENT V, LLCFORESITE CAPITAL OPPORTUNITY FUND V, L.P.FORESITE CAPITAL OPPORTUNITY MANAGEMENT V, LLCJAMES TANANBAUM

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO SCHEDULE 13D ea176678-13da2fsdeve2_pardes.htm SC 13D/A 124707
  Complete submission text file 0001213900-23-028115.txt   126586
Mailing Address 2173 SALK AVENUE SUITE 250, PMB#052 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 250, PMB#052 CARLSBAD CA 92008 415-649-8758
PARDES BIOSCIENCES, INC. (Subject) CIK: 0001822711 (see all company filings)

IRS No.: 852696306 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-93142 | Film No.: 23807625
SIC: 2834 Pharmaceutical Preparations

Mailing Address 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO CA 94111
Business Address 600 MONTGOMERY STREET SUITE 4500 SAN FRANCISCO CA 94111 415 877 4887
FS Development Holdings II, LLC (Filed by) CIK: 0001822712 (see all company filings)

IRS No.: 852696944 | State of Incorp.: DE
Type: SC 13D/A